Radiopharmaceutical market for prostate cancer to reach $6.3b by 2030

Radioligand therapies are gaining significant traction in the treatment of prostate cancer.

The radiopharmaceutical market for prostate cancer is projected to reach $6.3b by 2030.

According to GlobalData, radioligand therapies (RLTs) are gaining significant traction in the treatment of prostate cancer, with major pharmaceutical companies leading the charge.

Bayer's Xofigo (radium-223 dichloride) set a precedent with its FDA approval for castration-resistant prostate cancer (CRPC), igniting interest in RLTs. This was further bolstered by Novartis's acquisition of Advanced Accelerator Applications, the developer of Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which targets prostate-specific membrane antigen (PSMA).

Pluvicto is also expected to see its revenue skyrocket from $980m in 2023 to $4.3b by 2030, surpassing Xofigo.

Thomas Wales, an analyst at GlobalData, highlighted the success of Pluvicto in the Phase III VISION trial, which showed improved imaging-based progression-free survival (PFS) compared to standard treatments.

Patients treated with Pluvicto had a median PFS of 8.7 months, more than double that of standard care at 3.4 months. Additionally, Pluvicto patients experienced a four-month increase in overall survival (OS).

Meanwhile, Eli Lilly is actively recruiting for a Phase III trial of lutetium (177Lu) zadavotide guraxetan, which GlobalData forecasts will generate $1.65b in sales by 2030. However, with clinical approval still pending, it does not pose a near-term threat to Pluvicto's market position.

AstraZeneca is advancing FPI-2265-202, targeting PSMA-positive mCRPC patients in a Phase II/III trial, with results expected by 2026. Whilst its sales projections are lower than Pluvicto’s, the potential of actinium-225 could impact the RLT landscape.

Wales noted that Novartis is seeking a label expansion for Pluvicto to treat mCRPC patients not previously treated with taxane-based chemotherapy.

The Phase III PSMAfore study indicates strong potential for long-term survival improvements with PSMA-targeting RLTs.

Moreover, Pluvicto is anticipated to lead the market until at least the end of the decade, though new radiation-emitting ligands may emerge later.

Also Read

Dental radiology equipment market to grow by $2.45b by 2028

What to expect with Australia’s $739m Frankston Hospital Redevelopment?

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit